A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 May 2018
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms LenCombo
- Sponsors Sanofi
- 25 May 2018 Planned End Date changed from 4 Jan 2019 to 28 Dec 2018.
- 25 May 2018 Planned primary completion date changed from 4 Jan 2019 to 28 Dec 2018.
- 11 Apr 2018 Planned End Date changed from 15 May 2019 to 4 Jan 2019.